![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
X
20
Dong Bang Future Tech & Life Co., Ltd. Hwaseong-si Kr, based in South Korea, is a pharmaceutical company.
One of their significant offerings is Ketoprofen, Process N, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2017-194 - Rev 03
This Chemical Type CEP, issued on April 17, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 922 associated with this CEP further emphasizes